The meeting of leprosy programme managers in the South-East (SE) Asia Region was convened by the WHO Regional Office for South-East Asia (WHO-SEARO) from 11 to 13 April 2023 in Kolkata, India. The meeting was attended by 40 participants, including 15 national focal points from nine countries, five e...xperts, partners, donors and WHO staff members, including those from the Global Leprosy Programme (GLP).
The objectives of the meeting were to:
- review the current situation and progress of leprosy elimination in the Member States;
- discuss the updates on the new guidance and tools from the Global Leprosy Programme;
- facilitate experience-sharing and catalyse discussions to identify innovative practices, solutions and remaining gaps across countries to enhance leprosy elimination activities; and
- determine priority actions and support needs for accelerating leprosy elimination in the Region.
more
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
Ces Directives sur la qualité de l’eau de boisson : petits approvisionnements en eau ont été élaborées pour aborder les besoins et les possibilités associés aux petits approvisionnements afin de favoriser l’amélioration progressive vers des services d’alimentation en eau de boisson sû...rs et durables pour tous. Ces directives se fondent sur la principale recommandation des Directives de qualité pour l’eau de boisson de l’Organisation mondiale de la santé ; elles visent à fournir des orientations concernant l’application de cette recommandation aux petits approvisionnements en eau en particulier. Ces directives visent à aider les gouvernements et les praticiens à améliorer la sécurité sanitaire de l’eau de boisson fournie par de petits approvisionnements.
more
The new treatment recommendations that extend the 2018 treat all recommendation for adults with chronic HCV infection to include adolescents and children down to 3 years, and to align the existing recommended pangenotypic direct-acting antiviral (DAA) regimens (SOF/DCV, SOF/VEL and G/P) for adults, ...to those for adolescents and children. This alignment is expected to simplify procurement, promote access to treatment among children in low- and middle-income countries and contribute to global efforts to eliminate the disease
more
Было выявлено несколько ключевых факторов риска неинфекционных заболеваний (НИЗ), включая вредное употребление алкоголя. Алкоголь употребляет половина населения... Земли, а вредное употребление алкоголя является третьей по значимости причиной нездоровья и преждевременной смерти в мире
more
The report focuses on antibacterial resistance (ABR) in common bacterial pathogens. There is a major gap in knowledge about the magnitude of this problem. Antimicrobial resistance (AMR) threatens the effective revention and treatment of an ever-increasing range of infections caused by bacteria, para...sites, viruses and fungi. This WHO report, produced in collaboration with Member States and other partners, provides for the first time, as accurate a picture as is presently possible of the magnitude of AMR and the current state of surveillance globally. It examines the information on AMR, in particular antibacterial resistance (ABR), at country level worldwide.
more
The COVID-19 Supply Portal is a purpose-built tool to facilitate national authorities and all implementing partners supporting COVID-19 National Action Plans to request critical supplies.
This report represents the WHO-supported NTDs program activities and key performances in 2023. It is categorized into three sections: The first section states on the disease targeted for eradication (Guinea worm disease); the second section is on the
Preventive Chemotherapy (PC)-NTDs (Trachoma, ...Schistosomiasis, Soil Transmitted Helminthiasis, Onchocerciasis and Lymphatic Filariasis) and the third section is focused on the case management NTDs (Leishmaniasis, Leprosy, Human African
Trypanosomiasis, Noma and other skin NTDs).
more
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.